Have a heart: Include medicine cost in insurance

Cardiovascular disease requires long-term treatment and medicines are simply not within the reach of the poor in India, shows a study

sreelatha

Sreelatha Menon | July 2, 2016


#Insurance   #medicines   #heart   #cardiovascular disease   #poor   #India   #drugs   #medicine   #study   #University of Chicago   #Vandana Prasad   #Kiran Raj Pandey  


Should health insurance include the cost of medicine? That is the question raised by a recent study on India which seeks to measure the financial burden of cardiovascular diseases on people.

While it does not make any suggestions, it does point out that health insurance schemes in India do not cover medication costs. It further points out a known fact that 75 percent of health expenditure in India is out of pocket. And medications comprise 70 percent of these out-of-pocket expenses.
The study quantified these out-of -pocket expenses in purchasing cardiovascular medicines in India by measuring the resources available to individuals, subtracting daily medication costs to treat ischemic heart disease, and comparing the remaining available resources to established poverty thresholds set down by the C Rangarajan committee on poverty line.

The study led by Indian scientist Raj Kiran Pandey in the University of Chicago concluded that cardiovascular disease demands long-term treatment and the medicines are simply not within the reach of people in a low and middle income country like India.
It says that cardiovascular disease can lead to two outcomes in an Indian scenario: the patient decides not to take any medicine or the patient falls below the poverty line, incurring severe debt.

In order to assess the financial burden of heart disease, the researchers created five step-up treatment regimens for the most common cardiovascular medications in India. These were created by progressive addition of Aspirin, Hydrochlorothiazide, Losartan 25 mg, and Atorvastatin 10 mg or 40 mg. Daily cost from steps 1 to 5 increased from Rs 0.13, Rs 1.16, Rs 3.81 and Rs 10.07 to Rs 28.85.

The researchers deducted the expense at each stage from the resources available as per daily per capita expenditure data from the National Sample Survey. They compared the resultant income to the 2014 poverty threshold recommended by the expert group led by Rangarajan. This group had calculated Rs 32.4 as poverty threshold for rural India and Rs 46.9 as poverty threshold for urban India. This meant that 31 percent of rural population and 27 percent of the urban population is poor.

To the population below the poverty line, any health expenditure may be assumed to be unaffordable, the study says. For instance, buying a primary prevention regimen of an Aspirin and an anti-hypertensive (Hydrochlorothiazide 12·5 mg – step 2) would increase gross poverty ratios to 34 percent and 28 percent of rural and urban people respectively. This regimen could impoverish an additional three percent rural and one percent in urban population.
Hence, the treatment would mean swelling the numbers of the poor in India. Such being the case, the study offers no solutions but merely mentions that health insurance in India does not include medicine costs and generic drugs are not easily available to majority of people.

So for most people with disease, the only option is either to ignore it or take the pill and incur back-breaking debt. The study, “Financial Burden and Impoverishment Due to Cardiovascular Medications in Low and Middle Income Countries: An Illustration from India”, was published in PLOS in May this year.

Says lead author Kiran Raj Pandey: “17 million rural and 10 million urban people would be impoverished just because they took drugs they needed. Poverty figures would go up by 2 to 3 percent. That is a significant financial burden.”

Since medication is the reason for a huge amount of financial burden on the patients, including them in insurance may be an option, he told Governance Now. He also suggested subsidies for medication.

He says the study was for the whole of South Asia and India was just a case study and hence any one solution may not suit everyone.
The findings of the study have serious implications. They show that as much as 17 percent (93 mn) of the rural and 32 percent (76 mn) of the urban adult population may benefit from cardiovascular medicines. “If all of them were to buy cardiovascular medicines out of pocket, 4.05 percent of the urban adult population and 3.14 percent of the rural adult population could be impoverished due to the purchase. This could mean that 17 million people in rural areas and 10 million people in urban areas could be impoverished if all the people who would benefit from these medicines bought them out of pocket. Poverty gaps could increase by as much as 2.91 percent in rural areas and 2.88 percent in urban areas.”

Another problem area as far as chronic conditions like cardiovascular disease is concerned is the requirement for multi-drug regimen.
This poses a significant burden on people as chronic diseases like CVD are rarely treated with just one drug.

Although the Indian government has declared essential medicines free within the public health system, availability has often been reported to be anywhere between 0 to 30 percent. Health insurance schemes like the Rajeev Swasthya Bima Yojana and AarogyaShri are now available for some people, but they mostly cover hospital charges and do not provide long-term prescription coverage. As a result, 70 percent of out of pocket health expenditures in India are for purchasing drugs.

According to activist Vandana Prasad of the Jan Swasthya Abhiyan, this study has pointed to a serious lacunae in healthcare, as cardiovascular diseases and some other non-communicable diseases require chronic treatment for which there is no provision.


Menon is a freelance journalist.

(The story appears in the July 1-15, 2016 issue of Governance Now)

Comments

 

Other News

Maharashtra set to get first Shiv Sainik CM

The conundrum in Maharashtra is moving towards resolution, as the Shiv Sena has secured the support of the ideological opponents, the Congress and the NCP, to form the government, after the BJP, the party with the most seats, failed to muster the numbers. NCP chief Sharad Pawar has taken the

Vanni: In struggle of memory, pictures complement words

Gotabaya Rajapaksa, the new president of Sri Lanka, won the November elections that were held amid continued polarization in the island nation. As defence secretary, he had led the government’s decisive fight against the LTTE rebels in 2009, in which most of the guerrilla leaders were killed. Thus en

How Sahitya Akademi promotes India lit abroad

Sahitya Akademi, the autonomous organization under the ministry of culture, has been silently promoting Indian literature abroad through a host of activities, including promotion of translations. The Akademi has helped translate much-talked about Bangla novel ‘Herbert’ by Nabarun

Hotel responsible for vehicle in valet parking: supreme court

Once a guest hands over the car keys to the valet, the vehicle is under the hotel’s responsibility, and it will have to compensate any damage to it, the supreme court has ruled. In a judgment under the contract law, a bench of justices Mohan M Shantanagoudar and Ajay Rastogi has upheld

Homebuyers have filed 1,821 cases against builders

Amid oversupply, slackening demand and financial troubles, many builders have not been able to deliver homes to buyers, leaving the latter in the lurch. The buyers in turn have taken recourse to filing cases against builders: a total of 1,821 cases under the Insolvency and Bankruptcy Code (IBC) 2016 were p

Rajya Sabha looks back and forward on historic occasion

The beginning of its historic 250th session gave the upper house of parliament an opportunity to take stock of its past and its future, the challenges ahead and the ways to meet them. The house on Monday took up a discussion on ‘The Role of Rajya Sabha in Indian Polity and the Way Forw



Archives

Current Issue

Video

CM Nitish’s convoy attacked in Buxar

Opinion

Facebook    Twitter    Google Plus    Linkedin    Subscribe Newsletter

Twitter